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5-Hydroxytryptamine (5-HT) is proarrhythmic in atrial cells from patients in sinus rhythm (SR) via activation of 5-HT4 receptors, but its
effects in atrial cells from patients with atrial fibrillation (AF) are unknown. The whole-cell perforated patch-clamp technique was used to record
L-type Ca2+ current (ICaL), action potential duration (APD) and arrhythmic activity at 37°C in enzymatically isolated atrial cells obtained from
patients undergoing cardiac surgery, in SR or with chronic AF. In the AF group, 5-HT (10μM) produced an increase in ICaL of 115±21% above
control (n=10 cells, 6 patients) that was significantly smaller than that in the SR group (232±33%; p<0.05; n=27 cells, 12 patients). Subsequent
co-application of isoproterenol (1μM) caused a further increase in ICaL in the AF group (by 256±94%) that was greater than that in the SR group
(22±6%; p<0.05). The APD at 50% repolarisation (APD50) was prolonged by 14±3ms by 5-HT in the AF group (n=37 cells, 14 patients). This
was less than that in the SR group (27±4ms; p<0.05; n=58 cells, 24 patients). Arrhythmic activity in response to 5-HT was observed in 22% of
cells in the SR group, but none was observed in the AF group (p<0.05). Atrial fibrillation was associated with reduced effects of 5-HT, but not of
isoproterenol, on ICaL in human atrial cells. This reduced effect on ICaL was associated with a reduced APD50 and arrhythmic activity with 5-HT.
Thus, the potentially arrhythmogenic influence of 5-HT may be suppressed in AF-remodelled human atrium.
© 2006 Elsevier Inc. Open access under CC BY-NC-ND license.Keywords: Patch-clamp; Myocytes; Atrial fibrillation; L-type calcium current; Action potentials; 5-HT; Isoproterenol1. Introduction
Atrial fibrillation (AF) is the most common sustained
arrhythmia in the developed word and its prevalence will
increase with the aging of the population [1]. The occurrence of
AF may be related to structural heart disease, but in many cases
there is not a clear aetiology. One of the factors that has been
postulated to be responsible for the origin and maintenance of AF
is the release of 5-hydroxytryptamine (5-HT, serotonin) from
aggregating platelets in human atria [2,3]. 5-HT is a naturally
occurring monoamine, widely distributed in the animal kingdom,
which exerts complex effects throughout the body, including the
gastrointestinal and cardiovascular systems [4,5]. 5-HT has been
shown to act, via 5-HT4 receptors [6], as a positive inotropic,
chronotropic and lusitropic agent in the human atrium [7]. 5-HT⁎ Corresponding author. Tel.: +44 141 3302723; fax: +44 141 3308106.
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Open access under CC BY-NC-ND license.increases the L-type Ca2+ current, ICaL, using the same
biochemical pathway as isoproterenol (ISO), a β-adrenoceptor
agonist, through activation of cyclic AMP [8]. The 5-HT-induced
increase in peak ICaL density has been associated with a
prolongation of the early plateau phase of the action potential
duration (APD50) and with arrhythmic activity in atrial myocytes
from patients in sinus rhythm (SR) [9]. However, it is not known
if the ability of 5-HT to increase ICaL, APD50 and induce
arrhythmic activity is preserved in atrial myocytes from patients
with chronic AF. Another factor that may influence the
arrhythmogenic potential of 5-HT is chronic β-adrenoceptor
antagonist treatment of patients in SR prior to surgery [9–11].
The ability of 5-HT to increase ICaL, APD50 and to cause
arrhythmic activity in human atrial myocytes is increased by
chronic β-blockade in myocytes from patients in SR [9], but the
influence of chronic β-blockade on the electrophysiological
effects of 5-HT in myocytes from patients with AF is unknown.
There has been only one previous study of 5-HT and AF, which
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not of β-adrenoceptors, in the fibrillating human atrium [12].
The aims of this study were to investigate the effects of 5-HT
with and without ISO on ICaL, action potential duration (APD),
cellular effective refractory period (cERP) and cellular ar-
rhythmic depolarisations (cADs) in atrial myocytes from
patients with chronic AF, and to compare these with the effects
in atrial myocytes from patients in SR. We also assessed the
influence of chronic treatment of patients with a β-adrenoceptor
antagonist on the electrophysiological actions of 5-HT in atrial
myocytes from patients with and without AF.
2. Methods
2.1. Tissue and cell isolation
Procedures for obtaining human tissue were approved by the
local ethical committee and conform to the institutional guidelines.
This investigation conforms to the principles outlined in the
Declaration of Helsinki [13]. Samples of the right atrial appendage
were obtained from 81 consenting patients undergoing cardiac
surgery; 66 in SR and 15 in chronic AF. Cardiac rhythm was
determined from the pre-operative electrocardiogram, and duration
of AF was confirmed from the patients' medical records. Atrial
myocytes were isolated enzymatically as described previously [9].
2.2. Electrical recording techniques
The whole-cell perforated patch-clamp technique was used
to record ICaL, APD, cERP and cADs as described before [9].
Cells were superfused at 37°C with a physiological solution
containing (mM): NaCl (130), KCl (4), CaCl2 (2), MgCl2 (1),
glucose (10), HEPES (10), pH 7.4. To record ICaL, a pipette
solution containing (mM): CsCl (30), HEPES (5), MgCl2 (1),
Cs methanesulfonic acid (100), NaCl (5), nystatin (0.18) was
used. To record action potentials, a pipette solution containing
(mM): KCl (30), HEPES (5), MgCl2 (1), K methanesulfonic
acid (100), NaCl (5), nystatin (0.18) was used. Using these
solutions, a liquid junction potential of +5.0±0.2mV (n=6)
was measured (bath relative to pipette) and was compensated
for prior to seal formation. The series resistance in cells from
patients with and without AF was 9.5±0.3MΩ (n=99 cells)
and 10.4±0.2MΩ (n=352 cells), with a mean cell capacity of
92±2pF and 78±1pF (p<0.05), respectively. Capacitative
transients were compensated electronically from the recordings,
and the voltage drop across the series resistance was also
compensated (68–80%). The software program WinWCP (J.
Dempster, University of Strathclyde, UK) was used to stimulate
and record electrical activity.
2.3. Experimental protocols
The voltage dependency of ICaL was measured from a holding
potential of −40mV, with pulses of 250-ms duration at 0.33-Hz
increasing in steps of 10mV, up to +40mV. The time-dependent
effect of drugs was measured on peak ICaL with depolarising
pulses from −40 to +10mV (0.2Hz). Actions potentials werestimulated at the physiological rate of 75 beats/min (bpm) using
5-ms current pulses of 1.2× threshold strength, after current
clamping resting cells at −80mV, and keeping the holding
current (<150pA) constant thereafter throughout all recording
protocols in each cell. The holding current density (pA/pF) was
found not to be significantly different between cells from patients
in SR and AF, with or without prior treatment with a β-
adrenoceptor antagonist. The cellular ERP was measured using a
standard S1–S2 stimulation protocol, with an 8-pulse condition-
ing train delivered at 75bpm, and with S1 and S2 pulses of equal
magnitude. The S1–S2 interval was shortened in 10-ms steps, and
the cERP was defined as the longest S1–S2 interval which failed
to elicit an S2 action potential of amplitude >80% of the
preceding S1 action potential. The APD was calculated as the
interval between the action potential upstroke and repolarisation
to the level of 50% (APD50) and 90% (APD90) of the upstroke
amplitude. ICaL and/or action potentials and the cERP were
recorded before, and 90s after, drug additions and again 180s
after removal of drugs. The spontaneous development of cellular
arrhythmic depolarisations was recorded during the measurement
of the cERP protocol. Cellular ADs were defined as any transient
depolarisation during phase 3 or a transient depolarisation of
>3mV during phase 4.
2.4. Data analysis and statistics
Cells were excluded from analysis if either the APD50 or
peak ICaL decreased irreversibly during the protocol. Concen-
tration–response data for the effect of 5-HT on peak ICaL were
fitted iteratively (Graphpad Prism) using a variable slope
sigmoidal concentration–response curve. Time-dependent inac-
tivation of peak ICaL was fitted by a bioexponential function
[32]. All data have been analysed using cell means, except
when stated that patient means were used. Mean±standard error
of the mean (SEM) values were compared using paired or
unpaired Student's t-test, with p<0.05 regarded as statistically
significant. A Fisher's Exact Test was used to assess the inci-
dences of arrhythmic activity between groups of cells. To
permit sub-analysis within the SR group, data have been used
from 27 patients in SR who were included in a previous publi-
cation [9].
2.5. Drugs
5-HT and ISO (Sigma) were prepared as 10mM stock
solution in distilled water. Nifedipine (Sigma) and GR-113808
(a gift from Johnson and Johnson Pharmaceutical Research and
Development) were dissolved in dimethyl sulfoxide at 10mM
and subsequently diluted in physiological solutions.
3. Results
3.1. PatientsT clinical characteristics
Clinical characteristics of patients in SR or with chronic AF
(>6months) are shown in Table 1. Those patients with prior
treatment with β-adrenoceptor antagonists were treated for at
Fig. 1. Effects of 5-HT on ICaL current–voltage relationship. An example of
original ICaL traces obtained from a cell from a patient in SR (left panel) or with
AF (right panel), during depolarising voltage clamp pulses (250ms) from
−40mV to +40mV, in 10-mV incremental steps, from a holding potential of
−40mV, under control conditions (open symbols) and in the presence of 5-HT at
10μM (closed symbols) is shown. As an inset, current–voltage relationships of
ICaL expressed in terms of current density, pA/pF, in cells from patients in SR
(n=28 cells, 16 patients) or with AF (n=21 cells, 11 patients) are shown. Values
are expressed as means±SEM.
Table 1
Patients' pre-operative clinical characteristics
SR AF
n (%) n (%)
Patients 66 15
Male/Female 46/20 70/30 9/6 60/40
Age 65±1 69±2
Surgery
CABG 55 (83) 1 (7)
AVR 2 (3) 3 (20)
MVR 1 (2) 7 (47)
AVR+MVR 0 (0) 1 (7)
CABG+AVR 7 (11) 1 (7)
CABG+MVR 1 (2) 1 (7)
MVR+RAA 0 (0) 1 (7)
Drugs
Ca2+ channel blocker 31 (47) 3 (20)
Beta blocker 47 (71) 8 (53)
ACE inhibitor 38 (58) 7 (47)
Nitrate 42 (64) 3 (20)
Diuretic 22 (33) 9 (60)
Lipid lowering 56 (85) 7 (47)
Digoxin 0 (0) 9 (60)
Warfarin 1 (2) 12 (80)
Symptoms
Angina 61 (92) 8 (53)
Palpitations 12 (18) 6 (40)
Hypertension 40 (61) 8 (53)
Hyperlipidaemia 52 (79) 5 (33)
Previous history
MI 29 (44) 1 (7)
Diabetes 12 (18) 2 (13)
LV function
–Normal 48 (73) 9 (60)
–Mild–moderate LVD 17 (26) 5 (33)
–Severe LVD 1 (2) 1 (7)
Values are numbers of patients (n and percent of total, respectively) with
selected clinical characteristics, who were in SR or with AF on the day of
surgery. Age is expressed as mean±SEM. CABG=coronary artery bypass
graft surgery, AVR=aortic valve replacement, MVR=mitral valve replace-
ment, RAA=replacement ascending aorta, ACE=angiotensin converting
enzyme, MI=myocardial infarction, LVD=left ventricular dysfunction.
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selective β1-adrenoceptor antagonist, namely atenolol (77% of
patients), bisoprolol (17%), metoprolol (4%); 1 patient received
the cardiac non-selective β-adrenoceptor antagonist, proprano-
lol (2%). Those patients with AF were treated with atenolol
(57%), bisoprolol (29%) or with the cardiac non-selective β-
adrenoceptor antagonist, carvedilol (14%). Patients received
their routine drugs on the day of surgery. Mean ventricular rate
was 66±2bpm in 66 patients in SR versus 69±5bpm in 15
patients with AF (p>0.05). The ventricular rate was reduced in
β-blocked (60±2bpm, n=47) compared to non-β-blocked
patients (76±3bpm, p<0.05; n=19) from the SR group of
patients. In patients with AF, the ventricular rate was similar in
β-blocked (72±7bpm, n=8) compared to non-β-blocked
patients (66±7bpm, p>0.05; n=7).3.2. Effects of 5-HT on ICaL and influence of chronic AF
The density of basal peak ICaL was smaller in cells from
patients with AF (−3.0±0.2pA/pF; n=50 cells, 14 patients)
than in cells from those in SR (−5.4±0.3pA/pF, p<0.05; 178
cells, 58 patients). Within the AF group of patients, no
significant difference was found in basal ICaL between patients
who had (−2.9±0.2pA/pF; n=9) and who had not (−3.2±
0.3pa/pF; n=5) undergone mitral valve replacement (MVR)
surgery. Examples of original ICaL recordings from a cell from a
patient in SR or with AF are shown in Fig. 1 in the absence
(upper panel) or in the presence (lower panel) of 5-HT (10μM).
The 5-HT-induced increase in the mean magnitude of ICaL in
cells from patients with and without AF is shown in Fig. 1
(inset). This increase in ICaL occurred without any change in its
voltage dependency, and was reversible on washout of 5-HT.
The concentration–response curves of the effect of 5-HT on
peak ICaL density (pA/pF) obtained in cells from patients with
and without AF, are shown in Fig. 2A. 5-HT (0.001–10μM)
elicited a concentration-dependent increase in the amplitude of
Fig. 2. Concentration-dependent effects of 5-HT on peak ICaL. Comparison of
the concentration–response relationship for 5-HT-induced increase in peak ICaL
density (pA/pF) in cells from patients in SR (0.001–10μM; solid squares;
n=23–52 cells, 11–31 patients) or with AF (0.001–10μM; solid circles; n=26–
31 cells, 12–14 patients) is shown in panel A. Values are means±SEM. The
increase in ICaL is expressed as absolute value of change compared to before the
addition of 5-HT. Comparison of the calculated best-fit values for the Emax (B)
and EC50 (C) are shown between cells from patients in SR or with AF. The
asterisk indicates p<0.05 (unpaired Student's t-test).
Fig. 3. Influence of chronic β-blockade on concentration-dependent effects of
5-HT on peak ICaL. Panel A shows a comparison of concentration–response
curves for 5-HT-induced increase of peak ICaL density (pA/pF) between cells
from patients in SR treated (BByes; n=15–37 cells, 7–22 patients) and not
treated (BBno; n=8–17 cells, 4–9 patients) with a β-adrenoceptor antagonist
(open symbols), and those from patients with AF treated (BByes; n=11–18
cells, 5–7 patients) and not treated (BBno; n=13–16 cells, 5–6 patients) with
a β-adrenoceptor antagonist (closed symbols). Comparison of the calculated
best-fit values for the Emax (B) and EC50 (C) are shown between groups of
patients. Asterisk denotes p<0.05 (paired or unpaired Student's t-test), with
NS equal to p>0.05 (not statistically significant).
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of 187±2% above control in cells from patients with AF. This
was significantly less than that produced by 5-HT in cells from
patients in SR (Emax=260±7%; p<0.05; Fig. 2B). In addition,
the concentration of 5-HT producing half-maximal response
(expressed as logEC50) was significantly higher in cells from
patients with AF (−6.35±0.02) than in cells from those in SR
(−6.84±0.17; p<0.05), indicating a reduced potency of 5-HT
(Fig. 2C). The Hill coefficient, a measure of cooperativity of the
agonist with the receptor, was 0.68±0.02 in cells from patients
with AF, not significantly different than in cells from those in SR
(0.66±0.14). A higher concentration of 5-HT (100μM) caused a
significantly smaller ICaL response in comparison to the 10μM
5-HT in all cells studied, with and without AF (not shown). The
5-HT4 antagonist GR-113808 at 1μMblocked the 5-HT-induced
increase of peak ICaL in cells from patients in SR (n=4 cells, 2
patients) or with AF (n=4 cells, 2 patients). Basal peak ICaL was
abolished by the Ca2+ channel blocker nifedipine at 10μM in
cells from patients in SR (3 cells, 2 patients) or with AF (3 cells,
2 patients).
3.3. Effects of 5-HT on ICaL and influence of chronic
β-blockade
Chronic β-blockade did not significantly affect basal peak
ICaL in cells from patients in SR (−5.5±0.3 versus −5.0±
0.5pA/pF; n=137 cells from 41 β-blocked patients and n=41cells from 17 non-β-blocked patients, respectively) or with AF
(−3.2±0.3 versus −2.9±0.3pA/pF; n=24 cells from 7 β-
blocked patients and n=26 cells from 7 non-β-blocked
patients). The influence of chronic treatment of patients with
a β-adrenoceptor antagonist on the concentration–response
curves of the effect of 5-HT on peak ICaL obtained in cells from
patients with and without AF is shown in Fig. 3A. The Emax of
the increase in ICaL by 5-HTwas greater in cells from β-blocked
patients compared with non-β-blocked patients in the AF group
(205±4% versus 158±1%; p<0.05) and SR groups (282±14%
versus 216±4%; p<0.05; Fig. 3B), respectively. Neither the
potency (Fig. 3C) nor the nH of the 5-HT concentration–
response curve was affected by chronic treatment of patients
with a β-adrenoceptor antagonist with and without AF. Similar
increases in Emax by 5-HTwere obtained when the comparisons
were made of patient means, from β-blocked and non-β-
blocked patients in AF (234±5% versus 171±2%; p<0.05) or
SR (316±17% versus 231±4%; p<0.05), respectively.
3.4. Effects of 5-HT, with and without ISO, on ICaL, and
influence of chronic AF
In subsets of cells from patients with or without AF, the
application of a maximal concentration of 5-HT (10μM) was
Table 2
Kinetic properties of the time-dependent inactivation of ICaL
τ1 (ms) τ2 (ms) A1 (%) A2 (%)
SR control 6.2±0.5 41±4 72±2 28±2
SR 5-HT 5.7±0.5 40±2 66±2⁎ 34±2⁎
SR 5-HT+ISO 5.5±0.4⁎ 41±2 60±3⁎ 40±3⁎
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ISO (1μM), in order to assess the ability of β-adrenoceptors to
increase peak ICaL after saturation of 5-HT4 receptors. Figs. 4A
and B show examples of this protocol, from a cell from a patient
in SR or with AF, respectively. 5-HT produced an increase in
peak ICaL that was significantly greater in cells from patients inFig. 4. Effects of 5-HT, with and without ISO, on peak ICaL. An example of the
time course of change in peak ICaL density (pA/pF) plotted at 5-s resolution, in
response to 10μM 5-HT, followed by the co-application of ISO at 1μM, and the
subsequent washout of drugs in a cell from a patient in SR or with AF are shown
in panels A andB, respectively. Inset traces (a–d) show original currents recorded
at the time points labelled. Panel C showsmean (±SEM) ICaL data, in the absence
(open bars), in the presence of 10μM5-HT (closed bars) or co-applied with 1μM
ISO (crossed bars), measured in cells from patients in SR (n=27 cells, 12
patients; open circles) or with AF (n=10 cells, 6 patients; closed circles).
Subsequent re-application of ISO alone following the washout of 5-HT+ISO is
also shown for both SR (n=7 cells from 5 patients) and AF (4 cells from 2
patients) groups. Asterisk denotes p<0.05 (paired or unpaired Student's t-test).
SR wash 7.8±0.9 52±3 71±2 29±2
AF control 14.7±1.7⁎ 69±11⁎ 80±4 20±4
AF 5-HT 12.4±2.6 71±14 74±3⁎⁎ 26±3⁎⁎
AF 5-HT+ISO 9.9±1.8⁎⁎ 65±12 62±7⁎⁎ 38±7⁎⁎
AF wash 16.9±3.3 85±12 77±3 23±3
Time-dependent inactivation of ICaL was fitted by a bioexponential function and
was defined by the following equation: ICaL(t)=A1.exp(− t/τ1)+A2.exp(− t/τ2)+C,
where A1, A2 and τ1, τ2 are the amplitudes and decay time constants of the
respective exponential components, and C is the steady-state amplitude. Data
are expressed as mean±SEM in cells from patients in SR or with AF, in the
absence or in the presence of 5-HT (10μM), or co-applied with ISO (1μM). The
asterisks indicates p<0.05 vs. SR control (⁎) or vs. AF control (⁎⁎), using paired
or unpaired Student's t-tests, as appropriate.SR than that in cells from patients with AF (232±33 versus
115±21% above control; p<0.05; Fig. 4C). Subsequent co-
application of ISO further increased peak ICaL in both groups,
but by a relatively greater increase in cells from patients with
AF (256±94% greater than with 5-HT alone) than in cells from
patients in SR (22±6% greater than with 5-HT; p<0.05).
Although the absolute ICaL density in the presence of 5-HTwith
or without ISO was significantly less in cells from patients with
AF than that in cells from patients in SR (Fig. 4C), the relative
increase with ISO (to 273±38% above control, p<0.05, with
SR; and to 324±56% above control, p<0.05, with AF) was not
significantly different between the groups (p>0.05). Following
washout of 5-HT and ISO, the subsequent application of ISO
alone increased ICaL, in a similar manner to the co-application
of ISO with 5-HT, in both groups (Fig. 4C).
In the same set of cells, we analysed the kinetics properties of
the time-dependent inactivation of basal and stimulated peak
ICaL (Table 2). The fast (τ1) and the slow (τ2) inactivation time
constants were increased in cells from patients with AF
compared to cells from patients in SR. 5-HT had no significant
effect on τ1 and τ2 in cells from patients with and without AF.
However, their respective fractions A1 and A2 were altered by
shifting the ICaL inactivation from the fast to the slow phase.
Co-application of 5-HT with ISO decreased τ1, but not τ2, in
both group of cells, and this was associated with a reduced A1
and an increased A2.
3.5. Effects of 5-HT on APD characteristics and influence of
chronic AF
The basal APD50 was longer in cells from patients with AF
(40±3ms; n=37 cells, 14 patients) compared to cells from
patients in SR (17±2ms, p<0.05; n=58 cells, 24 patients). By
contrast, the APD90 was significantly shortened in cells from
patients with AF (203±8ms) compared to cells from patients in
SR (239±11ms; p<0.05). Within the AF group of patients, no
significant differences were found in basal APD characteristics
between patients who had (n=5) and who had not (n=9)
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action potential recordings illustrating the effects of 5-HT in a
cell from a patient in SR (left panel) or with AF (right panel),
both treated with a β-adrenoceptor antagonist. In these
examples, 5-HT (10μM) caused a prolongation of the APD50,
without affecting the late repolarisation and the cERP. Mean
data demonstrated that the 5-HT-induced prolongation of the
APD50 in the AF group was significantly smaller than that in the
SR group (Fig. 5B; p<0.05). This effect was fully reversible
after 3-min washout. There was no significant effect of 5-HT on
other action potential measurements including APD75, APD90,
cERP, overshoot, amplitude and maximum upstroke velocity in
either the cells from patients in SR or with AF.Fig. 5. Effects of 5-HT on action potentials characteristics. Representative
examples of original action potential recordings before (open circles), in the
presence of 10μM 5-HT (closed circles), and then following 3-min wash (open
squares), from cells from patients in SR (left panel) or with AF (right panel),
both treated with aβ-adrenoceptors antagonist, are shown in panel A. Cells were
paced at 75bpm. Dotted lines in bold show the level of 50% of the action
potential amplitude. The cellular ERP is indicated by solid bars and was defined
as described in the Methods section. Panel B shows the increase in APD50 (ms)
by 5-HT (10μM), measured in cells from patients in SR (n=58 cells, 24
patients) or with AF (n=37 cells, 14 patients). Asterisk denotes p<0.05
(unpaired Student's t-test).3.6. Effects of 5-HT on APD characteristics and influence of
chronic β-blockade
In cells from patients in SR, 5-HT produced a significantly
greater prolongation of APD50 in cells from β-blocked (36±
6ms; n=37 cells, 15 patients) than non-β-blocked patients
(10±3ms, p<0.05; n=21 cells, 9 patients). By contrast, in
cells from patients with AF, there was no significant
difference in the 5-HT-induced prolongation of the APD50
between cells from the β-blocked (18±5ms; n=25 cells, 8
patients) and non-β-blocked patients (9±3ms, p>0.05; n=12
cells, 7 patients). These findings were confirmed by using
patient means for both β-blocked patients and non-β-blocked
patients in SR (33±6 versus 9±3ms; p<0.05) or AF (16±4
versus 9±4ms; p>0.05), respectively.
3.7. Effects of 5-HT, with and without ISO, on APD
characteristics, and influence of chronic AF
In a subset of cells, we investigated effects on action
potentials of the co-application of ISO (1μM) and 5-HT
(10μM), following 5-HT alone, i.e., using the same protocol
described earlier for ICaL. Fig. 6A shows examples of such
effects in a cell from a patient in SR (left panel) or with AF
(right panel). Mean data from 10 cells (3 patients) indicated
that ISO may further prolong APD50 in cells from patients
with AF (from 60±7 to 74±9ms; p<0.05; n=10 cells, 3
patients), but not in cells from patients in SR (from 63±9 to
69±9ms; p>0.05; n=16 cells, 5 patients), with no significant
effects on APD75, APD90 and the cERP. GR-113808 (1μM)
prevented the increase induced by 5-HT (10μM) of APD50 in
cells from patients in SR (n=8 cells, 3 patients) or with AF
(n=3 cells, 1 patient), but not that of ISO (1μM) in cells
from patients in SR (7 cells, 3 patients) or with AF (2 cells, 1
patients).
3.8. Effects of 5-HT, with and without ISO, on cADs, and
influence of chronic β-blockade
Cellular arrhythmic depolarisations were not observed in
any of the 37 cells from 14 patients with AF to which
10μM 5-HT was applied. In contrast, when 10μM 5-HT was
applied in 58 cells from 24 patients in SR, cADs, consistent
with early and delayed afterdepolarisations, occurred in 13 of
the cells studied (22%) from 9 patients (38%) (p<0.05;
Fisher's Exact Test). These cADs in response to 5-HT were
observed only in cells obtained from β-blocked patients (13
of 37 cells), while none were observed in cells from the
non-β-blocked patients (0 of 21 cells; p<0.05). This
difference remained significant when the comparison was
made by patient means (p<0.05). In a subset of cells from
patients with and without AF (Fig. 6B), when ISO (1μM)
was co-applied with 5-HT (10μM), we observed the
appearance of cADs in 15 out of 16 cells (94%) studied
from 5 patients in SR and in 3 out of 11 cells (27%) from 3
patients with AF. Both nifedipine and GR-113808 prevented
the 5-HT-induced cADs in cells from patients in SR (4 cells
Fig. 6. Effects of 5-HT, with and without ISO, on arrhythmic activity. Panel A
shows an example of original recordings of action potentials obtained from a cell
from a patient in SR (left panel) or with AF (right panel), before (open circle), in
the presence of 10μM 5-HT (solid circle), 10μM 5-HT+1μM ISO (striped
circle) and then following 3-min washout (open square) or attenuation of ISO-
induced cADs by 10μM nifedipine (solid square). Panel B shows the incidence
of cADs (%) in cells from patients with and without AF, which occurred during
the application of 5-HT at 10μM (closed bars) or co-applied with ISO at 1μM
(crossed bars). Asterisks denotes p<0.05 (Fisher's Exact Test).
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However, while GR-113808 did not prevent the ISO-induced
cADs in cells from patients in SR (7 cells, 3 patients) or
with AF (2 cells, 1 patients), nifedipine did in cells from
patients in SR (2 cells, 1 patient) or with AF (3 cells, 2
patients).4. Discussion
This study is the first, to our knowledge, to report that AF
is associated with a reduction of the effects of 5-HT on ICaL
and APD50 in human atrial cells. This was associated with a
loss of arrhythmic activity in cells from patients previously
treated with a β-adrenoceptor antagonist. The proarrhythmic
actions of 5-HT in humans have been known for a long time
[14] and support for its proarrhythmic effects has been
reported in several studies from patients in SR [2,9,10], but
there are no reports from patients with AF. Our study
supports the hypothesis that 5-HT may play a role in
initiating AF by promoting ectopic activity in patients in SR,
that is enhanced by chronic treatment of patients with a β-
adrenoceptor antagonist. However, once the arrhythmia is
maintained and the remodelling process has occurred, 5-HT
has a reduced efficacy and potency in activating the L-type
Ca2+ channels. Therefore, despite the possible release of 5-HT
in the fibrillating atria by platelets [2], its arrhythmic
influence may be attenuated. This suggests that the remodel-
ling processes induced by chronic AF may involve an
adaptive response including protection from these effects of
5-HT. In addition, since late repolarisation and cERP were
unaffected by application of 5-HT in cells from patients with
and without AF, it is unlikely that 5-HT plays a role in
maintaining the arrhythmia by affecting the minimum path
length required for re-entry [15]. The absence of arrhythmic
activity by 5-HT in cells from patients with AF, and the low
incidence of arrhythmic activity found in cells from patients
in SR, are in line with a lack of clinical evidence to support
5-HT as a major factor involved in initiating and maintaining
AF in humans [3]. Indeed, even in 5-HT-secreting tumour
diseases like the carcinoid syndrome, in which high plasma
levels of 5-HT have been detected, the incidence of AF is low
[2,3].
The mechanisms involved in the reduction of the
electrophysiological actions of 5-HT in cells from patients
with AF are not clear. The involvement of the 5-HT4
receptors and the L-type Ca2+ channels in the actions of 5-HT
in these cells has been established by the prevention of the
effects by the 5-HT4 receptor antagonist, GR-113808, or the
Ca2+ channel blocker, nifedipine. In our study, ISO, with or
without 5-HT, induced a relatively greater ICaL increase in
cells from patients with AF compared to cells from patients in
SR, suggesting that the L-type Ca2+ channel was not the
limiting factor for the 5-HT response. The enhanced ICaL
response to ISO in cells from patients with AF has been
reported by others [16–18], but the effects of 5-HT have not
been studied previously. A reduction of mRNA expression of
5-HT4 receptors in chronic AF has been reported [12], but
other mechanisms may also contribute to the reduced effects
of 5-HT in AF. For example, increased activity of protein
phosphatases in chronic AF has been shown to be associated
with reduced basal and ISO-activated ICaL currents [18], and
changes in protein phosphatases and/or kinases with AF could
contribute to the reduced efficacy of 5-HT on ICaL current
density. The ability of 5-HT to increase cyclic AMP and
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to be significantly less than that of ISO [6,19,20], although
similar increases in ICaL were induced by 5-HT and ISO in atrial
cells from patients in SR [8,19,21]. In addition, changes in the
coupling of the stimulatory or inhibitory G proteins with 5-HT
or ISO receptors may differently affect adenylate cyclase
activity leading to the phosphorylation/dephosphorylation of
the L-type Ca2+ channel [22,23]. These and other factors, such
as the expression of different 5-HT4 receptor subtypes in human
atrial cells that couple to different Gs/i proteins [24–26], may
possibly reflect a physiological adaptation to limit the Ca2+
overload associated with AF [27]. The reduced potency of 5-HT
on the ICaL response with AF may support altered receptor/
channel coupling, in line with the observation of a reduced
potency of ISO on contractile responses in atrial tissue from
patients with AF [28].
The proarrhythmic activity induced by β-adrenoceptor
agonists (e.g., isoproterenol) has been known for a long time
[29] and their ability to increase ICaL via activation of the cyclic
AMP cascade has been highlighted as the main trigger to induce
afterdepolarisations in human atrial cells [29,30]. Similarly,
5-HT, which activates the same biochemical pathway, has been
demonstrated to induce proarrhythmic activity in atrial cells
from patients in SR, particularly in those previously treated with
β-adrenoceptor antagonists [9,10]. The reduced efficacy and
potency of 5-HT to increase ICaL in cells from patients with AF
in the present study was associated with a loss of proarrhythmic
activity by 5-HT, which may be directly linked to the reduced
Ca2+ entry [31]. ISO caused a greater increase in ICaL when
compared to 5-HT in both the SR and AF groups, and this was
associated with a greater incidence in the occurrence of
arrhythmic activity. Similarly, it has been shown previously
that the partial 5-HT4 agonist prucalopride, in cells from
patients in SR, caused reduced Ca2+ entry when compared to
5-HT, and did not induce arrhythmic activity, while 5-HT, in
the same cells, did [32]. In addition, the L-type Ca2+ channel
blocker nifedipine prevented the appearance of 5-HT/ISO-
induced cADs, suggesting that increased ICaL and cellular Ca
2+
overloadmay play a major role in inducing cADs in human atrial
cells [9,31,32]. Further studies, for example, using a combina-
tion of electrophysiology and Ca2+ imaging techniques, are
needed to elucidate the mechanisms of the observed arrhythmic
activity.
The slowing of the time-dependent ICaL inactivation in AF is
consistent with other studies in which τ1 and/or τ2, were
increased in AF [17,33], possibly reflecting an adaptation to an
altered activity of the SR Ca2+ release channels and/or a reduced
Ca2+ influx through L-type Ca2+ channels [34,35]. By contrast,
5-HT and ISO decreased the fast time constant(τ1) of ICaL
inactivation in both the SR and AF groups, and shifted the fast
phase to the slow phase, suggesting an enhanced Ca2+-
dependent inactivation probably due the increased release of
Ca2+ by ryanodine receptors during stimulation [34].
One important factor that may affect 5-HT response in
human atrium is prior treatment with β-adrenoceptor antago-
nists [2,9,10,36]. The present study indicated that chronic β-
blockade increased the effects of 5-HT on ICaL in cells frompatients with and without AF. However, while chronic β-
blockade potentiated the effects of 5-HT on the APD50 and
arrhythmic activity in cells from patients in SR, it did not in cells
from patients with AF. In our study we report a prolonged basal
APD50, together with a reduced basal APD90, in cells from
patients with AF, consistent with other studies [37,38], but in
contrast to other reports of no change in the APD50 [39] or
reduced APD50 with AF [33,40]. Since a maximal concentration
of ISO was capable of further prolonging the APD50 during
perfusion with 5-HT, the prolonged basal APD50 found with AF
in our study was not preventing a further increase with 5-HT.
While it has been reported that the levels of mRNA of human
atrial 5-HT4-, β1- and β2-adreno-receptors were unaffected by
chronic β-blockade in cells from patients with and without AF
[12], the interaction of complex “electrophysiological” [41] and
“pharmacological” [42] remodelling processes may alter the
balance of outward and inward currents which determine the
APD50 and attenuate the effect of chronic β-blockade on the
ICaL responses to 5-HT.
In conclusion, AF is associated with a reduced efficacy and
potency of 5-HT to increase ICaL in human atrial cells. The
reduced Ca2+ current is associated with a reduced duration of
the early plateau phase of the action potential and an absence of
arrhythmic activity with 5-HT. The ability of ISO to cause a
relatively greater increase in ICaL than 5-HT in cells from
patients with AF, compared with those in SR, suggests that the
reduced efficacy of 5-HT observed with AF was not due to
reduction in L-type Ca2+ channels but may involve other
factors, such as reduced density of the 5-HT4 receptors or
alterations of coupling mechanisms. Thus, the potentially
arrhythmogenic influence of 5-HT may be suppressed in
human atrium that has been remodelled by AF.
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